EXPEREO
10.4.2024 15:01:30 CEST | Business Wire | Press release
Expereo, the world leading global intelligent internet company that connects people, places and things anywhere today announces the appointment of Ben Elms as Chief Executive Officer and Irwin Fouwels as Executive Chairman, effective May 1st, 2024.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240410648166/en/
Ben Elms (Photo: Business Wire)
This strategic move is part of Expereo's commitment to driving sustained growth and building on its legacy of innovation and global customer success. With their combined experience in the telecommunications and technology sectors, Elms and Fouwels bring a wealth of expertise and leadership to their new roles within the business.
As CEO, Ben Elms will be responsible for driving the company's strategic vision, enhancing operational efficiency, and fostering innovation to meet the evolving needs of Expereo's global customer base. He brings over 25 years of relevant experience having held key executive roles at prominent firms and prior to joining Expereo as the CEO of Vodafone Global Enterprise Business, serving its multinational customers around the world.
Since joining in 2022 as Chief Revenue Officer, Elms has successfully led transformative initiatives such as expereoOne Expereo’s digital customer experience platform and driven its direct enterprise go-to-market strategy. This has positioned Expereo as a recognized global leader in delivering unique transformative customer value through its global enterprise network and cloud access solutions. In the first quarter of this year, Expereo launched its Enhanced Internet proposition, optimizing global cloud application performance through a proprietary AI-driven routing optimization platform. Leveraging Elms’ strong background in IoT and mobility, Expereo also added enterprise grade Fixed Wireless Access and Low Orbit Satellite solutions to its wide array of managed global connectivity solutions.
Elms commented; "I am honoured to lead Expereo during this exciting next phase of growth and innovation. Expereo has established itself as a global leader in internet-based connectivity solutions, and I look forward to working closely with the talented team to drive further success and deliver unparalleled value to our direct enterprise and wholesale customers. We have a strong foundation and a reputation for excellence in the industry. I am thrilled to lead the company with Irwin’s support as Executive Chairman. With the entire team we will capitalize on new opportunities, further expand our market presence, and drive continued innovation including driven by increased adoption of AI and the opportunities that creates for Expereo – “faster to the future”."
Fouwels, assuming the role of Executive Chairman brings a strategic mindset and a passion for innovation which has contributed to Expereo’s success. As Expereo CEO over the last decade, he has transformed and scaled Expereo to the world leading global intelligent internet company delivering unparalleled internet performance, led the company through multiple investor rounds and a series of acquisitions whilst delivering strong financial performance and investor returns.
Fouwels commented; “It is a privilege working with the global Expereo team and its investment partners over the last decade delivering unique value to our customers in a dynamic technology and telecoms market. We have been pivotal in transforming the way global enterprises architect global connectivity and application performance, leveraging the agility of the internet, whilst making it enterprise grade in terms of performance and security. And this anywhere on the globe, through any access technology.
Over the last two years Ben as CRO has been invaluable in accelerating our growth path, strengthening our go to market in direct enterprise whilst ensuring scalability throughout the organization, driving further automation, transformation and building global recognition of the Expereo brand and notably transforming expereoOne to a unique digital customer experience and platform. expereoOne turns the fragmented global internet landscape into a unique one-touch customer experience and has grown significantly with the addition of a large number of globally recognised large multinational enterprise customers. Ben has also brought in exceptional talent, strengthening the team as a foundation for further growth and solid financial performance. I am very much looking forward to working alongside Ben providing strategic guidance and supporting Expereo's leadership team”.
With Elms’ and Fouwels’ combined leadership, industry knowledge and track record of success they are confident in accelerating Expereo’s growth trajectory, and in delivering exceptional value to their customers and partners.
About Expereo
Expereo is the world leading intelligent internet company that connects people, places, and things anywhere. Solutions include Global Internet, SD-WAN/SASE, and Enhanced Internet. With an extensive global reach, Expereo is the trusted partner of 60% of Fortune 500 companies. It powers enterprise and government sites in more than 190 countries, with the ability to connect to any location worldwide, working with over 2,300 partners to help customers improve productivity and empowering their networks and cloud services with the agility, flexibility, and value of the Internet, with optimal network performance.
Expereo was acquired in Feb 2021, by Vitruvian Partners which acquired a majority shareholding from Seven2.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240410648166/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 10:00:00 CEST | Press release
REACH study met its first primary endpoint, showing that Broncho‑Vaxom® (OM‑85) was associated with a 28-38% reduction in respiratory tract infection rates at 12 months and 29-41% reduction at 24 months, comparing post-treatment versus pre-treatment initiation.1 The reduction was observed regardless of the frequency of respiratory tract infections in the previous year (1-3, >3) and across age subgroups (1-5, 6-11, 12-17, 18-64, >64 years).1 By reflecting everyday clinical practice and capturing episodes that necessitated a visit to the doctor, these extensive data offer critical new evidence of the therapy’s long-term relevance for patients suffering from recurrent respiratory tract infections. Evaluating a vast cohort of more than 15,790 paediatric, adolescent, adult and elderly patients in China, Italy, and Belgium, REACH represents the largest and only multi-country real-world evidence study to date for Broncho-Vaxom®.1,2 The study cohort includes patients with different co-morbidit
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
